Development of systemically-deliverable oncolytic adenovirus
| Project/Area Number |
24890130
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
KURODA Shinji 岡山大学, 医学部, 客員研究員 (60633758)
|
|---|
| Project Period (FY) |
2012-08-31 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 腫瘍選択的増殖型アデノウイルス / ウイルス療法 / 陽イオンリポソーム / ナノテクノロジー / 全身投与 / 腫瘍選択的増殖型アデノウイルス製剤 |
|---|
| Research Abstract |
We previously established telomerase-specific oncolytic adenovirus (Telomelysin). Since the application of Telomelysin is basically restricted to local injection because of nonspecific capture in the liver and inactivation by immune system, we investigated the possibility of systemic delivery of Telomelysin by combining with one of the common nanomaterials, liposomes. TelomeScan, modified Telomelysin expressing green fluorescent protein (GFP), was alternatively used in this study. TelomeScan plasmid DNAs encapsulated by liposomes (Lipo-TelomeScan-pDNA) showed potent cytotoxic effects in vitro study against various types of cancer cells by yielding vigorous virus progenies. Especially, Lipo-TelomeScan-pDNA produced significantly strong cytotoxic activity against HCT-116, a human colon cancer cell line, compared to control plasmid DNA encapsulated by liposomes. In vivo examination is ongoing to evaluate the availability of Lipo-TelomeScan-pDNA for systemic delivery.
|
Report
(3 results)
Research Products
(3 results)
